Medical Research Council Team Identifies Critical GPX4 Protein Shield Protecting 'Zombie' Senescent Cells in Aggressive Tumors

MRC researchers find that blocking the GPX4 protein triggers ferroptosis in senescent cells, offering a new way to reduce tumor size and improve cancer survival.

By: AXL Media

Published: Apr 25, 2026, 6:35 AM EDT

Source: Information for this report was sourced from EurekAlert!

The Hidden Vulnerability of Non-Dividing Tumor Cells

Modern oncology has long focused on halting the unconstrained division of cancer cells, yet a silent subpopulation known as senescent cells often persists within tumors. These "zombie-like" cells stop dividing but remain metabolically active, frequently increasing in number following standard chemotherapy treatments. According to the MRC Laboratory of Medical Sciences (LMS), while these cells do not directly expand a tumor's physical footprint, they secrete harmful molecules that drive metastasis and suppress beneficial immune activity. A joint study with Imperial College London has now pinpointed a specific biochemical tightrope these cells walk, revealing a new opening for targeted pharmaceutical intervention.

Identifying the Protective Shield of GPX4

The breakthrough came through an extensive screening process involving 10,000 covalent compounds designed to bind with previously "undruggable" proteins. Lead author Mariantonietta D’Ambrosio and her colleagues narrowed this vast library down to four promising senolytic agents, three of which were found to inhibit a protective protein labeled GPX4. Senescent cells produce high levels of GPX4 to stave off ferroptosis, a form of programmed cell death triggered by high iron concentrations and reactive oxygen species. Without this protein, the internal damage caused by the cell's own iron levels becomes fatal, effectively removing the biological shield that allows these "zombie" cells to survive within the tumor microenvironment.

Compounding the Damage of Traditional Chemotherapy

The presence of senescent cells is often an unintended side effect of the very treatments meant to cure cancer. Many chemotherapy drugs successfully block proliferation by forcing cancer cells into senescence, but the resulting cells can provoke increased aggressiveness in the remaining tumor. D’Ambrosio explained that for a long time, senescence was viewed as a positive outcome because it stopped tumor growth, but the negative side effects—including the recruitment of detrimental immune cells—necessitate a secondary treatment phase. By introducing GPX4 inhibitors after initial chemotherapy, clinicians could potentially clear out the remaining senescent cells before they can trigger a relapse or spread.